Moderna, Inc. (MRNA)

Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies

Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up

Moderna stock fires past 52-week high: what's behind Friday's rally?

Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure

Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?

3 Stocks That Have More Than Doubled the S&P 500’s Return This Year

Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?

Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets

Cedar Grove Capital Q3 2026 Portfolio Update

Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure

Tempus Announces Multi-Year Collaboration with Moderna and Merck

Is Now the Time to Cash Out of the S&P 500's Top 3 Stocks of 2026?

Moderna Is Up 545% in 2026: Take Profits Now, or Keep Buying?

Nasdaq, S&P 500 Score New Highs as Tech Takes Flight

Moderna (NASDAQ:MRNA) Hits New 52-Week High – Time to Buy?

Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher

Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up

Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips

Dow Futures Chart Over 400 Points Higher After Weak Jobs Data

Wall Street Breakfast Podcast: No Sprint For Nike Yet